Mr. Cameron Groome reports

MICROBIX ANNOUNCES EXTENSION OF WARRANT EXPIRY DATE

Microbix Biosystems Inc. has applied to the Toronto Stock Exchange to extend the term of an aggregate of 5.75 million common share purchase warrants which were issued in connection with Microbix's May 19, 2021, prospectus and private placement financings.

The warrants now entitle holders to purchase common shares of Microbix at a price of 80 cents until May 19, 2023. Microbix has applied to the TSX to extend the term of the warrants by one year. The warrant extension is approved by the company's board of directors but remains subject to TSX acceptance. The TSX Company Manual requires disclosure of warrant amendments to be made by press release at least 10 business days prior to the effective date. Accordingly, the term extensions will not be effective until May 29, 2023. warrant holders will therefore not be permitted to exercise warrants between May 19, 2023, and May 29, 2023. All other warrant terms will remain unchanged.

The warrant series for which term extensions are being sought are 87.9 per cent held by parties that are arm's length to Microbix. Term extensions for the 12.1 per cent of warrants held by Microbix insiders will be contingent on disinterested shareholder approval, and insiders will not be permitted to exercise such warrants unless and until such approval is obtained. Microbix proposes to include the warrant extension in respect of insiders as an item of business at the company's next shareholder meeting. All proposed warrant term extensions are subject to TSX approval.

The decision to seek extension of the term of these warrants was undertaken by the board of directors. After analysis, the board concluded that additional capital could be put to effective use by Microbix and that improving the prospect of the exercise of these warrants at 80 cents could help provide additional capital without the discounts or transactional costs associated with new private placements or public offerings of equity.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

About Microbix Biosystems Inc.

Microbix Biosystems creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting $2-million per month. It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of 10 international distributors. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA (Therapeutic Goods Administration) registered, Health Canada establishment licensed, and provides CE-marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the Toronto Stock Exchange and OTCQX, and headquartered in Mississauga, Ont., Canada.

We seek Safe Harbor.